SMAIO Publishes its 2023 Annual Results

Regulatory News:

SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French player specialized in complex spine surgery with a global offer comprising software, adaptative implants and related services, today published its 2023 annual results¹ approved by the Board of Directors on April 15, 2024.

Philippe ROUSSOULY, Chairman and CEO of SMAIO, said: “The year 2023 marked a major turning point in SMAIO's history with the achievement of our 3 main objectives. First of all, the FDA's 510(k) certification of the customized version of our surgical planning software enabled us to receive a $3 million payment from our American partner, NuVasive. This demonstrates our expertise and paves the way for the upcoming release of a brand-new surgical planning platform incorporating artificial intelligence to model the spine and provide practitioners with an optimized simulation of the surgical outcomes to be achieved. In the second part of the year, we activated several major user centers of SMAIO solutions in the US, demonstrating the increasing adoption of our technology by surgeons and validating the relevance of the various training programs we have conducted in the US over the past months. Finally, we have strengthened our financial structure through non-dilutive funding of €2.5 million, providing us with the necessary resources to continue deploying our growth strategy focused on the North American market."

Full-year 2023 results

SMAIO SA

Simplified income statement (SMAIO SA – parent Company - in €m)	2023	2022
Sales	7.6	2.4
Capitalized production	1.1	0.7
Operating income	8.9	3.2
Operating expenses	(8.2)	(7.2)
Operating profit/(loss)	0.7	(4.0)
Exceptional income/(expenses)	-	6.6